We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for sparsentan (Seqirus Pty Ltd)
Active ingredients
sparsentan
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
film-coated tablet
Indication
For the treatment of primary immunoglobulin A nephropathy (IgAN) in adults with a urine protein excretion ≥ 1.0 g/day
Therapeutic area
Immunology